Dr. Alexander T. Urquhart
Claim this profileShaw Cancer Center
Studies Breast Cancer
Studies Cancer
3 reported clinical trials
8 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
ER positive
PR positive
2Cancer
ER positive
HER2 positive
PR positive
Affiliated Hospitals
Clinical Trials Alexander T. Urquhart is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
More about Alexander T. Urquhart
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Alexander T. Urquhart has experience with
- Durvalumab
- Cyclophosphamide
- Doxorubicin
- Paclitaxel
- Olaparib
- Radiation Therapy
Breakdown of trials Alexander T. Urquhart has run
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander T. Urquhart specialize in?
Alexander T. Urquhart focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Alexander T. Urquhart currently recruiting for clinical trials?
Yes, Alexander T. Urquhart is currently recruiting for 2 clinical trials in Edwards Colorado. If you're interested in participating, you should apply.
Are there any treatments that Alexander T. Urquhart has studied deeply?
Yes, Alexander T. Urquhart has studied treatments such as Durvalumab, Cyclophosphamide, Doxorubicin.
What is the best way to schedule an appointment with Alexander T. Urquhart?
Apply for one of the trials that Alexander T. Urquhart is conducting.
What is the office address of Alexander T. Urquhart?
The office of Alexander T. Urquhart is located at: Shaw Cancer Center, Edwards, Colorado 81632 United States. This is the address for their practice at the Shaw Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.